Camurus AB products

episil^® oral liquid is a medical device for treatment of inflammatory and painful conditions in the oral cavity. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces, as well as severe inflammation caused by e.g. oral mucositis, a common and serious side effect of cancer treatment. In contact with the buccal membrane, episil^® transforms into a thin protective layer of gel, offering effective pain relief for up to 8 hours. episil^® oral liquid is based on Camurus’ FluidCrystal^® topical bioadhesive technology.

Buvidal® buprenorphine injection depots are indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment, and intended for use in adults and adolescents aged 16 years or over.

Camurus` clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

Camurus’ FluidCrystal injection depot is designed to provide treatment efficacy over extended periods – from days to months – with a single injection. It has the potential to reduce the burden of daily medication while increasing adherence to therapy. FluidCrystal^® is suitable for biological peptides as well as small molecules.

FluidCrystal topical bioadhesive is a liquid product that forms a bioadhesive film when applied to body tissues. The film acts as an invisible patch, slowly and accurately releasing the active ingredient for the treatment, systemically or locally. It also acts as a protective barrier for sensitive and inflamed tissues. The bioadhesive formulation is suitable for the prolonged local release of active ingredients on the skin and on the mucous membranes of for example the mouth, nose, and throat.

FluidCrysta nanoparticles can resolve bioavailability issues for water and lipid-soluble pharmaceuticals or biodegradation-sensitive drugs, such as peptides and proteins. FluidCrystal nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. Investigational medicinal products based on this technology are administered either parenterally via injections, or as a liquid sprayed onto the skin or mucous membranes.